Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 7708 results

  1. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development [GID-TA10777] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

      Status ...

    Highly specialised technologies guidance
    Topic selection

  3. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development [GID-TA11410] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development [GID-TA11100] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Leriglitazone for treating andrenoleukodystrophy [ID3903]

    In development [GID-TA11445] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    Awaiting development [GID-TA11367] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Awaiting development [GID-TA11406] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

    Technology appraisal guidance
    In development

  10. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    In development [GID-TA10596] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development [GID-TA10046] Expected publication date: 22 November 2017

    Technology appraisal guidance
    In development

  12. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development [GID-TA10966] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

    Awaiting development [GID-TA10198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095

    Awaiting development [GID-TA10993] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development [GID-TA10089] Expected publication date: 15 November 2017

    Technology appraisal guidance
    In development